EUVIMEDEUVIMED entdecken
Open Access

Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction

Yu-Chen Wang iD, Yen Chin Koay iD, Calvin Pan, Zhiqiang Zhou iD, Wilson Tang iD, Jennifer Wilcox iD, Xinmin S Li iD, Alexia Zagouras, Francine Marques iD, Hooman Allayee iD, Federico E Rey iD, David M Kaye iD und 4 weitere

Circulation Research · 16.02.2024 · 134 (4) · 371-389

DOI: 10.1161/circresaha.123.322381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 16.02.2024. Verfasst von Yu-Chen Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, Department of Microbiology, Immunology and Molecular Genetics, and Department of Human Genetics, Univ…. Hauptthemen laut MEDLINE: Heart Failure, Sirtuin 3, Cardiomyopathies, Propionates. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult. METHODS: Metabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts. RESULTS: The protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated diastolic dysfunction, metabolic remodeling, oxidative stress, inflammation, gut microbiota dysbiosis, and intestinal epithelial barrier damage. In the heart, IPA suppressed the expression of NNMT (nicotinamide N-methyl transferase), restored nicotinamide, NAD + /NADH, and SIRT3 (sirtuin 3) levels. IPA mediates the protective effects on diastolic dysfunction, at least in part, by promoting the expression of SIRT3. SIRT3 regulation was mediated by IPA binding to the aryl hydrocarbon receptor, as Sirt3 knockdown diminished the effects of IPA on diastolic dysfunction in vivo. The role of the nicotinamide adenine dinucleotide circuit in HFpEF was further confirmed by nicotinamide supplementation, Nnmt knockdown, and Nnmt overexpression in vivo. IPA levels were significantly reduced in patients with HFpEF in 2 independent human cohorts, consistent with a protective function in humans, as well as mice. CONCLUSIONS: Our findings reveal that IPA protects against diastolic dysfunction in HFpEF by enhancing the nicotinamide adenine dinucleotide salvage pathway, suggesting the possibility of therapeutic management by either altering the gut microbiome composition or supplementing the diet with IPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSirtuin 3CardiomyopathiesPropionatesHumansMiceAnimalsStroke VolumeNADIndolesNiacinamide

Stichwörter der Autor:innen

NADheart failure, diastolicmicrobiotaniacinamidereceptors, aryl hydrocarbon

Substanzen

propionic acidNADSirtuin 3IndolesNiacinamidePropionates

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, Department of Microbiology, Immunology and Molecular Genetics, and Department of Human Genetics, University of California, Los Angeles (Y.-C.W., C.P., Z.Z., A.J.L.).
  • Cardiometabolic Medicine, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia (Y.C.K., J.F.O.).
  • Charles Perkins Centre, Sydney, New South Wales, Australia (Y.C.K., J.F.O.).
  • Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, OH (J.W., X.S.L., S.L.H.).
  • Stanford Department of Medicine, CA (A.Z.).
  • School of Biological Sciences, Faculty of Medicine, Monash University, Clayton, VIC, Australia (F.M.).

ORCID-Profile: Yu-Chen Wang, Yen Chin Koay, Zhiqiang Zhou, Wilson Tang, Jennifer Wilcox, Xinmin S Li, Francine Marques, Hooman Allayee, Federico E Rey, David M Kaye, John F O'Sullivan, Stanley L Hazen, Aldons J Lusis

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Wang, Y. C., Koay, Y. C., Pan, C., Zhou, Z., Tang, W., Wilcox, J., Li, X. S., Zagouras, A., Marques, F., Allayee, H., Rey, F. E., Kaye, D. M., O'Sullivan, J. F., Hazen, S. L., Cao, Y., & Lusis, A. J. (2024). Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction. Circulation Research, 134(4), 371-389. https://doi.org/10.1161/circresaha.123.322381

Vancouver

Wang YC, Koay YC, Pan C, Zhou Z, Tang W, Wilcox J, et al. Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction. Circulation Research. 2024;134(4):371-389. doi:10.1161/circresaha.123.322381

BibTeX
@article{Wang2024,
  author = {Wang, Yu-Chen and Koay, Yen Chin and Pan, Calvin and Zhou, Zhiqiang and Tang, Wilson and Wilcox, Jennifer and Li, Xinmin S and Zagouras, Alexia and Marques, Francine and Allayee, Hooman and Rey, Federico E and Kaye, David M and O'Sullivan, John F and Hazen, Stanley L and Cao, Yang and Lusis, Aldons J},
  title = {Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction},
  journal = {Circulation Research},
  year = {2024},
  volume = {134},
  number = {4},
  pages = {371--389},
  doi = {10.1161/circresaha.123.322381}
}
Kostenlos starten →